ISN 9.09% 6.0¢ isonea limited

makattack, comparing revenues in growth companies is almost an...

  1. 5,518 Posts.
    lightbulb Created with Sketch. 12
    makattack,
    comparing revenues in growth companies is almost an exercise in futility.
    Checking out how big a market may be and how tangible is market entry is much more important and I sugest the key.
    Internet sales like a hotmail type campaign have not worked (at this stage) but was a good angle to start with. Cannot fault the company for trying. I would fault them if they stop the internet presence.
    My understanding is that big deals with pharmacy groups are progressing. No doubt price and terms need to be agreed. Even an engineer like Korten had progressed this only a month in the job (according to presentations and talks).
    Just imagine what the new commercial oriented guys will do.
    Was lucky enough to meet Sales guy. He can crack big markets and has done so in the past. I feel confident.
    Pharmacy groups from overseas (Europe) have asked for the product apparantly.
    Only a matter of time


 
watchlist Created with Sketch. Add ISN (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.